683 Capital Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

683 Capital Management’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-27,698	Closed	-$1.37M	–	189
2019 Q3	$1.37M	Buy	27,698 +15,555	+128%	+$1.12M	0.15%	73
2019 Q2	$1.1M	Hold	12,143	–	–	0.1%	96
2019 Q1	$1.79M	Hold	12,143	–	–	0.16%	77
2018 Q4	$1.91M	Hold	12,143	–	–	0.12%	92
2018 Q3	$2.98M	Buy	+12,143	New	+$2.88M	0.19%	67

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LFAS

Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

683 Capital Management's DMK Position: Q4 2019 in Review

683 Capital Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2019, closing a stake of 27,698 shares — an estimated $1.37M sold.

683 Capital Management first reported a position in DMK in Q3 2018 and held it in 5 quarters. The position peaked at $2.98M in Q3 2018. 38 funds tracked by Wall St. Rank hold DMK as of Q4 2019.

683 Capital Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2019 after selling out during the quarter.
683 Capital Management sold 27,698 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2019, an estimated $1.37M.
683 Capital Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2018 and held it in 5 quarters.
683 Capital Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $2.98M in Q3 2018.
38 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2019.

Based on 683 Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.